Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 165 entries
Sorted by: Best Match Show Resources per page
What should we tell our patients with colorectal cancer about diet, supplements, and lifestyle?.

Clinical advances in hematology & oncology : H&O

Meyerhardt JA.
PMID: 27058565
Clin Adv Hematol Oncol. 2015 Oct;13(10):636-8.

No abstract available.

Cite
Meyerhardt JA. What should we tell our patients with colorectal cancer about diet, supplements, and lifestyle?. Clin Adv Hematol Oncol. 2015;13(10):636-8
Meyerhardt, J. A. (2015). What should we tell our patients with colorectal cancer about diet, supplements, and lifestyle?. Clinical advances in hematology & oncology : H&O, 13(10), 636-8.
Meyerhardt, Jeffrey A. "What should we tell our patients with colorectal cancer about diet, supplements, and lifestyle?." Clinical advances in hematology & oncology : H&O vol. 13,10 (2015): 636-8.
Meyerhardt JA. What should we tell our patients with colorectal cancer about diet, supplements, and lifestyle?. Clin Adv Hematol Oncol. 2015 Oct;13(10):636-8. PMID: 27058565.
Copy Download .nbib Format: NLM
Can radiotherapy be omitted in patients with localized hodgkin lymphoma?.

Clinical advances in hematology & oncology : H&O

[No authors listed]
PMID: 25003354
Clin Adv Hematol Oncol. 2014 Apr;12(4):247.

No abstract available.

Cite
Can radiotherapy be omitted in patients with localized hodgkin lymphoma?. Clin Adv Hematol Oncol. 2014;12(4):247
(2014). Can radiotherapy be omitted in patients with localized hodgkin lymphoma?. Clinical advances in hematology & oncology : H&O, 12(4), 247.
"Can radiotherapy be omitted in patients with localized hodgkin lymphoma?." Clinical advances in hematology & oncology : H&O vol. 12,4 (2014): 247.
Can radiotherapy be omitted in patients with localized hodgkin lymphoma?. Clin Adv Hematol Oncol. 2014 Apr;12(4):247. PMID: 25003354.
Copy Download .nbib Format: NLM
The future of immunotherapy as perioperative therapy in renal cell carcinoma.

Clinical advances in hematology & oncology : H&O

[No authors listed]
PMID: 28398283
Clin Adv Hematol Oncol. 2017 Feb;15(2):126-129.

No abstract available.

Cite
The future of immunotherapy as perioperative therapy in renal cell carcinoma. Clin Adv Hematol Oncol. 2017;15(2):126-129
(2017). The future of immunotherapy as perioperative therapy in renal cell carcinoma. Clinical advances in hematology & oncology : H&O, 15(2), 126-129.
"The future of immunotherapy as perioperative therapy in renal cell carcinoma." Clinical advances in hematology & oncology : H&O vol. 15,2 (2017): 126-129.
The future of immunotherapy as perioperative therapy in renal cell carcinoma. Clin Adv Hematol Oncol. 2017 Feb;15(2):126-129. PMID: 28398283.
Copy Download .nbib Format: NLM
Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition: Commentary.

Clinical advances in hematology & oncology : H&O

Fowler NH.
PMID: 28590462
Clin Adv Hematol Oncol. 2017 Mar;15(3):21-23.

No abstract available.

Cite
Fowler NH. Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition: Commentary. Clin Adv Hematol Oncol. 2017;15(3):21-23
Fowler, N. H. (2017). Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition: Commentary. Clinical advances in hematology & oncology : H&O, 15(3), 21-23.
Fowler, Nathan H. "Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition: Commentary." Clinical advances in hematology & oncology : H&O vol. 15,3 (2017): 21-23.
Fowler NH. Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition: Commentary. Clin Adv Hematol Oncol. 2017 Mar;15(3):21-23. PMID: 28590462.
Copy Download .nbib Format: NLM
Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition.

Clinical advances in hematology & oncology : H&O

[No authors listed]
PMID: 28590461
Clin Adv Hematol Oncol. 2017 Mar;15(3):1-24.

No abstract available.

Cite
Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition. Clin Adv Hematol Oncol. 2017;15(3):1-24
(2017). Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition. Clinical advances in hematology & oncology : H&O, 15(3), 1-24.
"Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition." Clinical advances in hematology & oncology : H&O vol. 15,3 (2017): 1-24.
Advances in lymphoma and leukemia from the 2016 American Society of Hematology annual meeting and exposition. Clin Adv Hematol Oncol. 2017 Mar;15(3):1-24. PMID: 28590461.
Copy Download .nbib Format: NLM
Genetic conditions associated with a predisposition to kidney cancer.

Clinical advances in hematology & oncology : H&O

[No authors listed]
PMID: 28591096
Clin Adv Hematol Oncol. 2017 Apr;15(4):239-241.

No abstract available.

Cite
Genetic conditions associated with a predisposition to kidney cancer. Clin Adv Hematol Oncol. 2017;15(4):239-241
(2017). Genetic conditions associated with a predisposition to kidney cancer. Clinical advances in hematology & oncology : H&O, 15(4), 239-241.
"Genetic conditions associated with a predisposition to kidney cancer." Clinical advances in hematology & oncology : H&O vol. 15,4 (2017): 239-241.
Genetic conditions associated with a predisposition to kidney cancer. Clin Adv Hematol Oncol. 2017 Apr;15(4):239-241. PMID: 28591096.
Copy Download .nbib Format: NLM
Unmet needs in the treatment of chronic lymphocytic leukemia: general discussion.

Clinical advances in hematology & oncology : H&O

[No authors listed]
PMID: 25856008
Clin Adv Hematol Oncol. 2014 Jan;12(1):11-3.

No abstract available.

Cite
Unmet needs in the treatment of chronic lymphocytic leukemia: general discussion. Clin Adv Hematol Oncol. 2014;12(1):11-3
(2014). Unmet needs in the treatment of chronic lymphocytic leukemia: general discussion. Clinical advances in hematology & oncology : H&O, 12(1), 11-3.
"Unmet needs in the treatment of chronic lymphocytic leukemia: general discussion." Clinical advances in hematology & oncology : H&O vol. 12,1 (2014): 11-3.
Unmet needs in the treatment of chronic lymphocytic leukemia: general discussion. Clin Adv Hematol Oncol. 2014 Jan;12(1):11-3. PMID: 25856008.
Copy Download .nbib Format: NLM
Highlights in T-cell lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition.

Clinical advances in hematology & oncology : H&O

[No authors listed]
PMID: 25856173
Clin Adv Hematol Oncol. 2014 Feb;12(2):6-18.

No abstract available.

Cite
Highlights in T-cell lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition. Clin Adv Hematol Oncol. 2014;12(2):6-18
(2014). Highlights in T-cell lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition. Clinical advances in hematology & oncology : H&O, 12(2), 6-18.
"Highlights in T-cell lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition." Clinical advances in hematology & oncology : H&O vol. 12,2 (2014): 6-18.
Highlights in T-cell lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition. Clin Adv Hematol Oncol. 2014 Feb;12(2):6-18. PMID: 25856173.
Copy Download .nbib Format: NLM
Function of the BTK pathway in B-cell malignancies.

Clinical advances in hematology & oncology : H&O

Berger JA.
PMID: 25856366
Clin Adv Hematol Oncol. 2013 Aug;11(8):3-6.

No abstract available.

Cite
Berger JA. Function of the BTK pathway in B-cell malignancies. Clin Adv Hematol Oncol. 2013;11(8):3-6
Berger, J. A. (2013). Function of the BTK pathway in B-cell malignancies. Clinical advances in hematology & oncology : H&O, 11(8), 3-6.
Berger, Jan A. "Function of the BTK pathway in B-cell malignancies." Clinical advances in hematology & oncology : H&O vol. 11,8 (2013): 3-6.
Berger JA. Function of the BTK pathway in B-cell malignancies. Clin Adv Hematol Oncol. 2013 Aug;11(8):3-6. PMID: 25856366.
Copy Download .nbib Format: NLM
Clinical use of BTK inhibitors.

Clinical advances in hematology & oncology : H&O

Wiestner A.
PMID: 25856368
Clin Adv Hematol Oncol. 2013 Aug;11(8):10-2.

No abstract available.

Cite
Wiestner A. Clinical use of BTK inhibitors. Clin Adv Hematol Oncol. 2013;11(8):10-2
Wiestner, A. (2013). Clinical use of BTK inhibitors. Clinical advances in hematology & oncology : H&O, 11(8), 10-2.
Wiestner, Adrian. "Clinical use of BTK inhibitors." Clinical advances in hematology & oncology : H&O vol. 11,8 (2013): 10-2.
Wiestner A. Clinical use of BTK inhibitors. Clin Adv Hematol Oncol. 2013 Aug;11(8):10-2. PMID: 25856368.
Copy Download .nbib Format: NLM
The importance of the BTK pathway in B-cell malignancies: discussion.

Clinical advances in hematology & oncology : H&O

[No authors listed]
PMID: 25856369
Clin Adv Hematol Oncol. 2013 Aug;11(8):12-3.

No abstract available.

Cite
The importance of the BTK pathway in B-cell malignancies: discussion. Clin Adv Hematol Oncol. 2013;11(8):12-3
(2013). The importance of the BTK pathway in B-cell malignancies: discussion. Clinical advances in hematology & oncology : H&O, 11(8), 12-3.
"The importance of the BTK pathway in B-cell malignancies: discussion." Clinical advances in hematology & oncology : H&O vol. 11,8 (2013): 12-3.
The importance of the BTK pathway in B-cell malignancies: discussion. Clin Adv Hematol Oncol. 2013 Aug;11(8):12-3. PMID: 25856369.
Copy Download .nbib Format: NLM
Highlights in chronic lymphocytic leukemia from the 2017 American Society of Hematology Annual Meeting and Exposition.

Clinical advances in hematology & oncology : H&O

[No authors listed]
PMID: 29742091
Clin Adv Hematol Oncol. 2018 Jan;16(1):1-28.

No abstract available.

Cite
Highlights in chronic lymphocytic leukemia from the 2017 American Society of Hematology Annual Meeting and Exposition. Clin Adv Hematol Oncol. 2018;16(1):1-28
(2018). Highlights in chronic lymphocytic leukemia from the 2017 American Society of Hematology Annual Meeting and Exposition. Clinical advances in hematology & oncology : H&O, 16(1), 1-28.
"Highlights in chronic lymphocytic leukemia from the 2017 American Society of Hematology Annual Meeting and Exposition." Clinical advances in hematology & oncology : H&O vol. 16,1 (2018): 1-28.
Highlights in chronic lymphocytic leukemia from the 2017 American Society of Hematology Annual Meeting and Exposition. Clin Adv Hematol Oncol. 2018 Jan;16(1):1-28. PMID: 29742091.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 165 entries